Epitalon: What the Research Shows

Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026

Epitalon (also written epithalon) is a synthetic peptide of four amino acids, designed from the make-up of epithalamin, a cattle pineal-gland extract, and promoted for longer telomeres (the caps on the ends of chromosomes), slower aging, deeper sleep and a longer life. Tested in people, in two small studies from its developers’ network: after a course of 10 or 20 days, night-time melatonin, or its by-product in urine, rose in people whose levels started low. The evidence in people stops there: those studies gave epitalon to 35 people, one unblinded eye study does not say how many it treated, and no published study in people has measured sleep, telomeres, aging, cancer or lifespan.

This review, part of our peptide library, sets out what has been tested and what hasn’t. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.

At a glance

FDA status
Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval.
Evidence in people
Three small studies from the developers’ network: melatonin rose in two; one unblinded eye study. No sleep study.
The claim you’ve heard
Lengthens telomeres and slows aging: lab studies of cells, animal studies with mixed results; not tested in people.
Doses tested in people
Into muscle: 0.01 mg a day for 10 days. No milligram-sized injection; none under the skin.
Sport
Not named on WADA’s 2026 or 2027 List. WADA says an unnamed peptide “may still be prohibited”.

What epitalon is

Epitalon is a chain of four amino acids, Ala-Glu-Asp-Gly (AEDG). The FDA describes it as “a synthetic tetrapeptide derived from the amino acid composition of low-molecular weight peptides in epithalamin, an extract originally obtained from the pineal gland of cattle”.

Epitalon is not epithalamin. Epithalamin is the extract, a mixture of peptides; epitalon is one synthetic sequence, and the FDA “considers epitalon and epithalamin as different substances”. A chemical database and the nominations sent to the FDA list “epithalamin” as another name for epitalon. Every long follow-up, every mortality figure and the milligram injection doses quoted for epitalon come from studies of the extract.

Forms. Epitalon exists as a free base and as an acetate salt. The FDA treats them as different substances, found that the clinical papers “do not always clearly identify” which was given, and calls inconsistent naming “a safety risk for patients as they may be dosed with a different bulk drug substance than the physician ordered.” N-acetyl epitalon is a separate entry in the federal substance registry; no study in people of any modified version was found.

Where it stands with the FDA

Status checked: November 19, 2026.

In plain words: epitalon is not an FDA-approved medicine and is not on the FDA’s list of ingredients for compounding (making a medicine for one patient on a prescription, under section 503A of federal drug law); the FDA’s staff proposed keeping it off. HHS, the federal department the FDA belongs to, says in a draft policy that it does not intend to act against compounding of single-ingredient epitalon acetate, injected under the skin or into a muscle in intermittent courses on a patient’s prescription, under set conditions; that is not FDA approval.

As of November 19, 2026, epitalon is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. In a draft interim policy announced on October 30, 2026, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician that compounds single-ingredient epitalon acetate as a subcutaneous or intramuscular injection “dispensed in intermittent courses” for a patient-specific prescription when the policy’s conditions are met; HHS’s notice says the policy “is not binding on HHS or the public”, and it is not FDA approval. The FDA’s own review proposed that epitalon “NOT be included” on that list; HHS says the advisory committee “voted in favor of inclusion”.

The FDA’s own review. Before its advisory committee met in July 2026, the FDA’s staff evaluated epitalon for one use, insomnia, as an injection under the skin, and concluded that the “physicochemical characterization, limited information on historical use, lack of evidence of effectiveness, and lack of safety information” for both forms “weigh against their being added to the 503A Bulks List.” They did not evaluate the other proposed uses, such as “anti-aging, longevity, lengthening telomeres in human cells”. The FDA has published no minutes or vote count for the committee’s vote, and an advisory vote does not bind it.

The FDA’s safety text. Epitalon was in the FDA’s Category 2, for nominated substances that may present significant safety risks, until April 2026. It left because its nominators withdrew, not because the FDA found it safe, and it is in no category today. The FDA says compounded drugs containing epitalon “may pose risk for immunogenicity for certain routes of administration”, and that it “has not identified safety-related information regarding epitalon for the proposed route of administration” and so “lacks sufficient information to know whether the drug would cause harm if administered to humans.” (Immunogenicity: an immune reaction to the peptide or its impurities; none has been reported or looked for.)

HHS’s draft policy and its conditions. For epitalon, HHS’s document identifies the acetate only and names only “subcutaneous or intramuscular injectable dosage forms that are dispensed in intermittent courses”. It names no capsule, no spray for the mouth or nose, no skin product, no blend and no use. HHS’s policy document does not define “intermittent courses”. Among its ten conditions:

  • “only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”;
  • a patient-specific prescription;
  • the label statement “This is a compounded drug product. Not for resale.”;
  • a certificate of analysis (a test report) for the raw ingredient;
  • reports of serious adverse events to the FDA and the states.

Among HHS’s reasons: “CDER’s safety concerns are mechanistic rather than based on observed harm, the limited controlled human exposure reported no side effects, and the documented regimens are intermittent rather than continuous” (CDER: the FDA’s drug center). It cites no source for that sentence. The FDA’s staff, on the same record: “there are no clinical data to support the safety of epitalon (free base) or epitalon acetate when used in humans.”

Sport. Epitalon is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 prohibits “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”; neither List says whether WADA treats epitalon under it. WADA’s note to the 2027 List: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”

Claims you’ll see, and why sources disagree

Pages about epitalon disagree for three reasons.

  • Two substances share one story. The extract’s mortality reports and milligram doses are routinely credited to epitalon; one clinic page’s reference list for epitalon cites the extract’s mortality paper.
  • Cells and slides are counted as human trials. One “study database” page presents a 2003 cell-culture paper as an “Open-label, non-randomized study in 14 elderly volunteers”; no such study was found. A sentence that telomeres lengthened “in the blood cells of patients” traces, in the encyclopedia article that carries it, to a slide on the developer’s website (which we did not open), not to a journal.
  • Animal results are worded as human ones. Clinic pages speak of “anti-tumor activity across many animal and human studies” and “extensive research involving both animal and human clinical trials”; the tumour studies are in mice and rats, and three small studies gave epitalon to people.

Where this review says “not tested in people”, that is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.

Claim Level of evidence Verdict
“Increases lifespan by lengthening telomeres in human cells” Lab studies Not tested in people. Seen in cultured cells, and repeated once by an independent group.
“a 28% decrease in overall mortality” The extract’s figure; for epitalon, animal studies, mixed That figure is from a 12-year report on the extract. No study in people of epitalon measured aging or survival; the mouse and rat lifespan results are mixed.
“Restores and normalizes melatonin levels”; “Better sleep” Melatonin: tested in people. Sleep: not tested Melatonin rose in people who started low, in two small unrepeated studies. No published study in people measured sleep.
“Anti-tumor effects” Animal studies Fewer tumours in some mouse and rat experiments, no change in others. Not tested in people; the FDA raises the opposite concern, from mechanism.
“generally well-tolerated” Tested in people: side effects not systematically recorded Not established. No harm reported in three small studies; nothing studied at the amounts clinic and seller pages describe.

What the evidence consists of

Tested in people

Study People Design What happened Funding or limits
Korkushko and colleagues, 2007 40 healthy people aged 60 to 79: 15 epitalon, 15 extract, 10 saline Randomized, saline placebo, blinding not described; epitalon injected into muscle daily for 10 days In those with low night-time melatonin, the 3 a.m. level went from 20±4 to 49±7 pg/ml on epitalon (12 people; p<0.05) and from 27±4 to 25±4 on saline (8). No change in the three who started normal The patent’s inventor is a co-author; no interest statement; a subgroup result
Ivko and colleagues, 2021; a companion report, apparently on the same women 75 women aged 40 to 50 on night shifts. The 35 with a normal urinary melatonin marker were an untreated reference group; of the 40 with a low marker, 20 got epitalon (the FDA’s count) “a randomized, placebo-controlled study” (the FDA); blinding not specified; a spray under the tongue for 20 days The marker “increased 1.7-fold” on epitalon, unchanged on placebo; two clock genes changed in blood cells. Better “psycho-emotional and general physical condition” in 83% against 25%; the FDA: “no details were provided” about how that was assessed Full text not read: as the FDA describes it. Authors declare no conflict; the spray was a commercial “dietary supplement”
Khavinson and colleagues, 2002 “162 patients (324 eyes)” with retinitis pigmentosa (a disease of the retina) “examined”; 46 controls; treated group’s size not stated Not blinded, no placebo, not randomized as far as the paper says; daily injections beside each eye for 10 days, against standard drugs “a positive clinical effect in 90% of the cases”; among controls, improvement “only in 31.5% of the cases” The developer’s own clinic; no interest statement; vision tests depend on effort

What these studies can’t tell us. None of the three studies was registered in advance, and none has been repeated. Neither melatonin study measured sleep; both results are hormone levels in people who started low. The FDA: “The potential therapeutic effect of changes in melatonin levels induced by these substances is unclear without a corresponding evaluation of clinical outcomes.” Its staff could not evaluate the full 2007 paper “because it was in the Russian language”; it was read in Russian for this review.

Reported in people

Two uncontrolled series appear only in the developer’s patent: 14 patients with age-related conditions and 11 with “aspirin bronchial asthma”, given injections into muscle for 10 days. The asthma series holds the only mention of sleep for people given epitalon: “sleep recovery” among improvements the patients themselves reported, with no measure, no numbers and no comparison group. No case report was found in PubMed.

Animal studies

  • Lifespan. In female mice given microgram doses under the skin five days a month, mean lifespan was 721 days against 685 in one study (up 5.3%) and unchanged in another; maximum lifespan rose in both. In rats on a standard day and night cycle it did not change.
  • Tumours. Fewer tumours in several mouse and rat experiments from the developers’ group and its co-authors (in one, 2 of 50 mice against 10 of 50); total tumour incidence unchanged in two mouse studies; no effect in a rat bladder-tumour model.
  • The FDA’s reading. Each mouse study used one fixed dose, only female mice and short exposure, so they “do not adequately inform the genotoxic or the carcinogenic potential of epitalon.” The FDA “did not identify” acute, repeat-dose, reproductive or two-year cancer studies.

Lab studies and how it is thought to work

The FDA: “The mechanisms by which epitalon regulates levels of melatonin and, possibly, modulates circadian rhythms are unknown.”

  • Telomeres (lab studies). In 2003 the developers reported that epitalon switched on telomerase (the enzyme that rebuilds telomeres) and lengthened them in cultured human fetal cells. In 2025 a London group with no author from the developers’ group reported the same general finding in two normal human cell types, at 20 times the 2003 concentration for three weeks; at four days it saw “No increase in telomere lengths” in one of them. Its authors declare “no competing interests”; the paper calls its peptide both bought from a supplier and “a gift for research use only” from another.
  • Cancer cells (lab studies). In the same paper telomeres lengthened within four days in two breast-cancer cell lines, by a different pathway.
  • Cells taken from people (lab studies). In blood cells from 11 men, treated in the dish, telomeres lengthened in 5, shortened in 2 and did not change significantly in 4.

Who produced the research

Of 165 PubMed records about epitalon (searched November 19, 2026), 106 (64.2%) list Vladimir Khavinson as an author and 111 (67.3%) list him or his colleague V.N. Anisimov, as do 102 (69.4%) of the 147 that are not reviews; 149 (90.3%) come from their group or from Russia. Khavinson, of the St. Petersburg Institute of Bioregulation and Gerontology, is the named inventor of the US patent on the peptide (granted 2004, now shown as expired). The group’s 2020 and 2021 papers state that the authors have no conflict of interest; its 2002 and 2007 papers on epitalon in people carry none. An all-positive record in people from one network, with no comparison of doses, is itself a reason for caution.

Dosing: what has been tested, what is used, and what the reasoning supports

This section reports and reasons; it recommends nothing. None of the three studies in people compared doses, so no dose can be called optimal.

Doses tested in people

Study People Dose Route How often and how long
Korkushko, 2007 15 people aged 60 to 79 0.01 mg (10 micrograms); 0.1 mg in the whole course Into muscle Daily at 10 a.m. for 10 days; one course
Khavinson, 2002 Treated group’s size not stated “5.0 µg into each eye”; “100.0 µg per course” Beside the eye Once a day for 10 days
Ivko, 2021, and its companion report 20 women A spray labelled as giving 0.5 mg a day; the amount absorbed is unknown Under the tongue Twice a day for 20 days
The developer’s patent (two series, not journal reports) 14 patients; 11 with asthma “10 μg per injection” Into muscle Daily for 10 days

(µg: micrograms.) No published study in people has given epitalon under the skin, in milligram amounts by any injection, as a capsule or as a nasal spray; none ran longer than 20 days, repeated a course, or identified the acetate as the form given. The 2007 authors put the dose ratio of epitalon to the extract at “1:500”, course against course (0.1 mg against 50 mg).

Doses in common use

These are amounts in circulation: practice that no trial set, reported so that a reader can see where each comes from and how it compares with what was studied.

  • Milligrams a day under the skin. US clinic websites, as the FDA found them in December 2025, described “doses ranging from 5 mg to 10 mg per day” as “an SC injection or oral supplement” (SC: under the skin); a protocol site states “5 to 10 mg per day via subcutaneous injection for 10 to 20 consecutive days”. No study in people used these amounts or this route: they are 500 to 1,000 times the 0.01 mg a day injected into muscle in the one study.
  • The prescriber monograph. A peptide society’s monograph, reproduced in the FDA’s briefing document, gives “10 mg IM daily for 10 days” (“100mg total”) or “10 mg every third day times 2 weeks” (“50 mg total”), twice a year (IM: into muscle), and says the society now uses the under-the-skin route. Number for number these are the extract’s regimens in the 2003 paper; 10 mg is 1,000 times the epitalon dose studied, and no study supports the change of route.
  • Timing and course length. A dose-chart site states “10 mg once daily x 10 consecutive days”, repeated “2–3x per year”, with evening dosing “for circadian support”; a clinic page describes “five nights a week” for “an eight-week course”. Repeat courses echo the developers, whose 2007 paper suggests, and did not test, two to three 10-day courses a year at 10 micrograms daily. The injection study dosed at 10 a.m., and no study in people ran longer than 20 days.
  • Product strengths. The FDA found “10 mg, 20 mg, 25 mg, 50 mg vials; 3 mg and 3.3 mg capsules; and an oral spray” on sale online. The smallest vial holds 100 times the whole course of the 2007 study (0.1 mg).

What the pharmacology supports, and what it doesn’t

  • Amount (measured in people only in micrograms by injection). Nothing published says what the milligram injections in circulation do that a 0.01 mg injection does not, for benefit or for harm.
  • Frequency (not measured; inferred). The FDA: “No pharmacokinetic data were found for epitalon (free base) or epitalon acetate.” A peptide this small would be expected to break down quickly, but the melatonin result was read after ten once-daily injections, and nobody has measured how long one dose lasts. The reasoning supports no schedule and no hour of the day.
  • Route (inferred). With no blood levels by any route, a result by one route says nothing about another, including under the skin.
  • Duration (measured in people: one course of 10 or 20 days). The FDA words its cancer concern around “chronic continuous exposures”, but says the intermittent mouse studies “do not adequately inform” the question, so intermittent use does not remove it.
  • Monitoring (inferred). None has been established. The FDA’s concerns point, by inference, to cancer history and screening and to reactions to injection.

Nobody knows how much of any dose reaches the blood, how long it stays, or what milligram doses or repeated courses do in people.

What common protocols get wrong

  • The extract’s doses credited to epitalon. A telehealth marketing article says its “5 to 10 mg per day” (practice no trial set) “comes from Khavinson’s Russian clinical and observational studies”; a supplement seller’s blog says “clinical studies consistently use brief courses of 10–20 days”, citing two papers on the extract. The group’s published injection into muscle was 0.01 mg a day; its 10 mg regimens are the extract’s.
  • An extract trial cited for the peptide. The prescriber monograph describes “a human trial done over a 12-year period with patients treated with epithalon” and a “28% decrease in overall mortality”; its footnote is the 2006 paper on the extract. It also names the third amino acid as asparagine (it is aspartic acid).
  • A cell study given a dose. The “study database” page that turns the 2003 cell paper into a volunteer study adds a “standard 10 mg IM course”.
  • Animal doses overstated. A protocol and shop site refers to “up to ~50 mg/day in some animal-era work”; the animal studies used 0.1 to 1 microgram per mouse or rat.
  • HHS’s policy described as permission. A pharmacy directory says pharmacies “may compound epitalon” under “HHS’s interim peptide policy of October 28, 2026”, and a health company’s guide says the policy “covers epitalon”. HHS said it “does not intend to take enforcement action”, in a draft announced on October 30 that names only epitalon acetate and is “not binding on HHS or the public”.

The dose is the prescriber’s decision for one patient.

Safety, and who should be most cautious

In the studies. No harm from epitalon has been reported, and almost nobody has looked: none of the three studies describes how side effects were sought. The 2007 paper’s abstract calls the preparations free of side effects and its body reports none; the eye study says even patients with a history of allergy “have not developed any side reactions, complications or other side effects”; the spray study, the FDA notes, “did not report safety data”. The whole published exposure by injection is one 10-day course in 15 people, plus the eye study’s patients.

Outside the studies. The FDA’s search of its adverse-event database through December 8, 2025 “retrieved no reports”; it adds that compounders “generally do not report adverse events to FDA”. Clinic and pharmacy pages that call epitalon “generally well-tolerated”, with “mild injection-site reactions”, rest on no study that recorded them, and the “no side effects” statements concern a dose 500 to 1,000 times smaller than the injections such pages describe.

The cancer question (theory, in both directions). People with cancer now or in the past have the most reason for caution, on mechanism alone. The FDA: “from the mechanistic standpoint, epitalon has the potential to be carcinogenic. Specifically, epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer.” The mouse studies point the other way, and the FDA does not accept them as settling it.

Situation What is known Basis
Pregnancy, breastfeeding No human data; no animal reproductive studies found. In one rabbit study a labelled signal appeared in fetal organs; the FDA cautions it may not have been epitalon The FDA’s review
Under 18 No study Study reports
Cancer, now or in the past No human data in either direction Theory, above
Repeated or longer courses; milligram doses; under-the-skin, capsule or nasal products No human safety data Study reports
Tested athletes Not named on WADA’s Lists; WADA urges “utmost caution” WADA

Product quality

  • The raw ingredient. The FDA’s staff found both forms “not well-characterized”. For the acetate, the form HHS’s policy names, a certificate showed 99.5% purity but “no information regarding the nature of individual impurities that can be present at up to the 1.0% level”, and “No bioburden/endotoxin test is mentioned” (tests for bacterial contamination). HHS’s draft policy says “lots from FDA-registered facilities report the endotoxin, microbial, and residual solvent results CDER found missing”; HHS did not release those certificates, so we could not check them.
  • Compounded injections. The FDA “was not able to identify any pharmacies that compound products containing any form of epitalon” in a web search. Its records hold two recalls of compounded “Epithalon” injections, 15 mg and 20 mg, both for lack of sterility assurance, and warning letters from 2020 and January 2026 that name epitalon among other products. None states its status today, and none shows those amounts were studied.
  • Products sold online. No published measurement of the purity, content or contamination of epitalon sold online was found; the one analysis, as a 2026 review describes it, “confirmed AEDG identity but did not evaluate pharmaceutical-grade purity, dosing accuracy, sterility, stability, or product safety”. Several sites say their product “is intended for research use only”; HHS’s draft policy concerns compounding on a patient-specific prescription and says nothing about such products.

What we make of it

This section is our reading of the evidence. It is a judgment, not a finding.

On the evidence, epitalon is unproven and experimental. Something real may be there: in two small controlled studies melatonin measures rose in people who started low, and an independent laboratory has repeated the telomere finding in cells. A benefit for sleep in older people with low melatonin is plausible on that basis; it has not been tested.

The claims run far ahead. Longer telomeres in people, slower aging and lower mortality rest on cells, on animals and on a different substance. The widest gap is in dose: the amounts in circulation were carried over from the extract and are untested, for benefit and for safety. And the telomere finding that makes epitalon attractive is also the basis of the FDA’s cancer concern, which the record cannot settle either way.

What would have to be true: that the melatonin rise holds up in a blinded, registered trial by an independent group and brings a benefit a person can feel, such as better sleep, and that long-term studies answer the cancer question.

For whom epitalon might ever be considered, after what, with what monitoring and when to stop are our Medical Director’s to state.

Peptide care at Rock Creek Wellness

Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.

So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.

What would change this review

  • A blinded, registered trial with a clinical outcome, such as sleep. ClinicalTrials.gov’s one record that mentions epitalon is a skin serum of five peptides; the EU register has none (searched November 19, 2026).
  • A rule or a revised HHS policy. The FDA “will not issue a final determination” until “all reviews have been finalized.”

Common questions

Does epitalon lengthen telomeres?

In cultured cells, yes; in people, that has not been tested. No published study has measured telomeres in people given epitalon, and the one independent cell study also found lengthening in breast-cancer cell lines.

Does epitalon help with sleep?

That has not been tested: no published study in people measured sleep. Two small studies found higher melatonin measures in people who started low; for insomnia, the one use it evaluated, the FDA found “a lack of evidence to support the effectiveness of epitalon (free base) or epitalon acetate”.

Is epitalon safe?

That is not established. No harm was reported in the three small studies, but none says how side effects were sought, and nothing has been studied at the milligram amounts that clinic and seller pages describe.

Is epitalon FDA-approved, and can a doctor prescribe it?

It is not FDA-approved or on the FDA’s list of substances for compounding. The federal sources we read give no yes or no about prescribers: their conditions attach to compounding and to the product. HHS’s draft interim policy speaks only of single-ingredient epitalon acetate as a subcutaneous or intramuscular injection, dispensed in “intermittent courses” on a patient-specific prescription. State pharmacy rules apply separately.

How much epitalon do people take, and how often?

The one study that injected it into muscle gave 0.01 mg a day for 10 days. Clinic and seller pages describe 5 to 10 mg a day under the skin for 10 to 20 days, which is practice no trial set: those amounts come from the extract and are 500 to 1,000 times the dose studied. The dose is the prescriber’s decision for one patient.

Sources

Show all 38 sourcesHide sources
  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026: Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate). US Food and Drug Administration, 2026.
  2. Introduction to the briefing documents (Pharmacy Compounding Advisory Committee, July 23-24, 2026). US Food and Drug Administration, 2026.
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US Food and Drug Administration, 2026.
  4. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. US Food and Drug Administration, 2026.
  5. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
  6. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
  7. Warning letter: Tailor Made Compounding LLC, MARCS-CMS 594743. US Food and Drug Administration, 2020.
  8. Warning letter: GenoGenix LLC, MARCS-CMS 718739. US Food and Drug Administration, 2026.
  9. Drug recall enforcement reports (openFDA, searched for “epithalon”). US Food and Drug Administration, 2026.
  10. Global Substance Registration System (GSRS): EPITALON, UNII O65P17785G. US National Institutes of Health, National Center for Advancing Translational Sciences, 2026.
  11. 2026 Prohibited List. World Anti-Doping Agency, 2025.
  12. 2027 Prohibited List. World Anti-Doping Agency, 2026.
  13. The Prohibited List (with the Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List). World Anti-Doping Agency, 2026.
  14. NCT07888595 (Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks). ClinicalTrials.gov, US National Library of Medicine, 2026.
  15. EU Clinical Trials Register, search “epitalon”. European Medicines Agency, searched 2026.
  16. Epitalon, PubChem CID 219042. US National Library of Medicine, 2026.
  17. PubMed search: epitalon, epithalon or epithalone in title or abstract. US National Library of Medicine, searched 2026.
  18. Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application, US 6,727,227 B1. United States patent (read on Google Patents), 2004.
  19. Нормализующее влияние пептидов эпифиза на суточный ритм мелатонина у старых обезьян и пожилых людей (Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people). Успехи геронтологии (Advances in Gerontology), 2007.
  20. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuroendocrinology Letters, 2002.
  21. AEDG Peptide Regulation of the Expression of Human Circadian Rhythm Genes upon Accelerated Aging of the Pineal Gland. Advances in Gerontology, 2021.
  22. AEDG Peptide Regulates the Expression of Circadian Genes Clock, Cry2, Csnk1e in Human Immune Cells. World Heart Journal, 2021.
  23. Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters, 2003.
  24. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine, 2006.
  25. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 2003.
  26. Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes. Bulletin of Experimental Biology and Medicine, 2019.
  27. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025.
  28. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mechanisms of Ageing and Development, 2001.
  29. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 2003.
  30. Effect of epitalon and melatonin on life span and spontaneous carcinogenesis in senescence accelerated mice (SAM). Вопросы онкологии (Voprosy Onkologii), 2005.
  31. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine, 2007.
  32. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer, 2002.
  33. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Letters, 2002.
  34. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo, 2006.
  35. Effect of vilon and epithalone on induction and growth of induced bladder neoplasms in rats. Вопросы онкологии (Voprosy Onkologii), 2001.
  36. Fluorescent microscopic study of epithalon binding in maternal and fetal rabbit tissues in health and under conditions of placental insufficiency. Bulletin of Experimental Biology and Medicine, 2005.
  37. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. International Journal of Molecular Sciences, 2026.
  38. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 2025.